

### **Current Reporting of Material Corporate Events**

As of July 22, 2021, the number of shares outstanding of our Common Stock was 537,881,194.

#### **Disclosure Statement Pursuant to the OTC Pink Basic Disclosure Guideline**

Corporate Events:

#### **Appointment of new Director, and issuance of Warrants to purchase Common Stock of Issuer.**

Curative Biotechnology, Inc. (the “Company”) announced via press release on July 15, 2021, that Marc Drimer, CPA has joined the Company’s board of directors (“Board”) as an independent director and Chairman of the Audit Committee. Mr. Drimer has over 35 years of experience in all areas of corporate governance, compliance, and operations in the financial services industry. He has held management positions in London and Geneva serving as Controller of Hertz Europe and Allied Maintenance. He is a graduate of Brooklyn College with a BS in Accounting and holds an MBA in Finance from New York University Graduate School of Business. Mr. Drimer is currently the CFO for Lampert Capital Markets, Inc. and is responsible for financial and operational aspects of the firm. Additionally, he serves as the Financial and Operations principal and Options and Municipal Bond principal of Lampert Capital Markets. He has served as both a CEO and CFO for a number of brokerage firms and investment banks, responsible for the origination and syndication of numerous private placements and initial public offerings in a broad range of industries. He holds the Series 4, 7, 24, 27, 53, 63 and 79 licenses.

As consideration for Mr. Drimer’s services on the Board, the Company issued Mr. Drimer a warrant (the “Warrant”) to purchase 1,000,000 shares of Common Stock, having an exercise price of \$0.124 per share, and a term of three (3) years which vests as follows: (i) 250,000 shares on July 14, 2021, (ii) 250,000 shares on November 14, 2021, (iii) 250,000 shares on March 14, 2022, and (iv) 250,000 shares on July 14, 2022, all subject to Mr. Drimer continuing his services as a member of the Board.

Mr. Drimer’s work address is 1825 NW Corporate Blvd., Ste 110, Boca Raton, FL 33431. Except for the Warrant described herein, Mr. Drimer does not own any securities of the Company. Mr. Drimer does not have any family relationships between any of the Company’s directors or officers.

**Disclosure Certification**

Principal Executive Officer

I, I Richard Garr, certify that I have reviewed this Material Corporate Event of Curative Biotechnology, Inc.

7/22/2021

/s/ I Richard Garr